[go: up one dir, main page]

GB0707208D0 - Novel disease treatments - Google Patents

Novel disease treatments

Info

Publication number
GB0707208D0
GB0707208D0 GBGB0707208.5A GB0707208A GB0707208D0 GB 0707208 D0 GB0707208 D0 GB 0707208D0 GB 0707208 A GB0707208 A GB 0707208A GB 0707208 D0 GB0707208 D0 GB 0707208D0
Authority
GB
United Kingdom
Prior art keywords
disease treatments
novel disease
novel
treatments
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0707208.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto Superiore di Sanita ISS
Original Assignee
Istituto Superiore di Sanita ISS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Superiore di Sanita ISS filed Critical Istituto Superiore di Sanita ISS
Priority to GBGB0707208.5A priority Critical patent/GB0707208D0/en
Publication of GB0707208D0 publication Critical patent/GB0707208D0/en
Priority to PCT/EP2008/004992 priority patent/WO2008125366A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0707208.5A 2007-04-13 2007-04-13 Novel disease treatments Ceased GB0707208D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0707208.5A GB0707208D0 (en) 2007-04-13 2007-04-13 Novel disease treatments
PCT/EP2008/004992 WO2008125366A2 (en) 2007-04-13 2008-04-11 Treatment of autoimmune diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0707208.5A GB0707208D0 (en) 2007-04-13 2007-04-13 Novel disease treatments

Publications (1)

Publication Number Publication Date
GB0707208D0 true GB0707208D0 (en) 2007-05-23

Family

ID=38116725

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0707208.5A Ceased GB0707208D0 (en) 2007-04-13 2007-04-13 Novel disease treatments

Country Status (2)

Country Link
GB (1) GB0707208D0 (en)
WO (1) WO2008125366A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2390334C1 (en) * 2008-12-17 2010-05-27 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Федерального агентства по здравоохранению и социальному развитию" Method of treating multiple sclerosis
WO2013192100A1 (en) * 2012-06-18 2013-12-27 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods and compositions for detecting jc virus
WO2014110127A1 (en) 2013-01-08 2014-07-17 Enzo Biochem, Inc. Diagnosis and treatment of viral diseases
US9617607B2 (en) 2013-01-08 2017-04-11 Enzo Biochem, Inc. Diagnosis and treatment of viral diseases
ITRM20130206A1 (en) 2013-04-05 2014-10-06 Univ Roma GENOTYPE VERSIONS OF EPSTEIN BARR VIRUSES AND THEIR USES AS POSSIBLE RISK PREDICTORS, THERAPEUTIC BIOMARKERS AND TARGETS IN MULTIPLE SCLEROSIS
WO2021215428A1 (en) * 2020-04-22 2021-10-28 日華化学株式会社 Nucleic acid detection method and oligonucleotide probe
US20240309451A1 (en) * 2020-12-29 2024-09-19 The Board Of Trustees Of The Leland Stanford Junior University Diagnostics and therapeutics for ebv in ms and other autoimmune diseases
CN114990240B (en) * 2022-06-01 2024-05-10 昆明理工大学 Multiplex qPCR Assays for Detection of Exogenous Pathogens in Gynecological Diseases

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
EP0397798A4 (en) * 1988-02-03 1991-10-30 Xoma Corporation Therapeutic use of anti-t cell immunotoxin for autoimmune diseases
IL89953A (en) * 1989-02-03 1994-04-12 Xoma Corp Pharmaceutical composition comprising anti-t cell immunotoxin for use in treating autoimmune disease
CA2059824A1 (en) * 1991-02-26 1992-08-27 Thomas M. Aune Hybridomas and monoclonal antibodies that inhibit anti-cd3-stimulated t cell proliferation
CA2116526A1 (en) * 1991-08-28 1993-03-18 William V. Williams T cell receptor-based therapy for rheumatoid arthritis
US7888458B1 (en) * 1993-11-30 2011-02-15 John B. Harley Diagnostics and therapy of epstein-barr virus in autoimmune disorders
US7790153B2 (en) * 1994-04-12 2010-09-07 Research Development Foundation Method of treating rheumatoid arthritis using orally administered type one interferons
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US7273613B1 (en) * 1997-01-13 2007-09-25 The Board of Regents, The University of Oklahoma Diagnostics and therapy of Epstein-Barr virus in autoimmune disorders
KR20020027311A (en) * 1999-05-07 2002-04-13 제넨테크, 인크. Treatment of Autoimmune Diseases with Antagonists Which Bind to B Cell Surface Markers
US20040002474A1 (en) * 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
CA2392456A1 (en) * 1999-11-24 2001-05-31 Oklahoma Medical Research Foundation Assays and therapies for latent viral infection
SE0002045D0 (en) * 2000-05-31 2000-05-31 Sahltech Ab New use
JP2004517839A (en) * 2000-12-11 2004-06-17 トゥフツ・ユニバーシティ Treatment and prevention of EBV infection and EBV-related disorders
US20030082138A1 (en) * 2001-09-18 2003-05-01 Chiron Corporation Methods for treating multiple sclerosis
DE10148417A1 (en) * 2001-09-29 2003-04-17 Andreas Schwarting Use of interferon-ß for the therapy of systemic lupus erythematosus
EP1455812A4 (en) * 2001-11-26 2006-03-22 Chiron Corp Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
US20060057107A1 (en) * 2001-12-21 2006-03-16 Shaked Ze Ev Combination treatment for multiple sclerosis
WO2004004798A2 (en) * 2002-07-03 2004-01-15 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
WO2004032828A2 (en) * 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
EP1613350B1 (en) * 2003-04-09 2009-03-18 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
WO2005009466A1 (en) * 2003-07-24 2005-02-03 Universita' Degli Studi Di Perugia Methods and compositions for increasing the efficiency of therapeutic antibodies using alloreactive natural killer cells
US20060257363A1 (en) * 2004-03-10 2006-11-16 Pepgen Corporation Treatment using an interferon
TW201422238A (en) * 2004-06-04 2014-06-16 Genentech Inc Use of CD20 antibody in treatment of multiple sclerosis and an article for the use
JP2008526998A (en) * 2005-01-13 2008-07-24 ジェネンテック・インコーポレーテッド Method of treatment
WO2007014238A2 (en) * 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. Single dose use of cd20-specific binding molecules

Also Published As

Publication number Publication date
WO2008125366A2 (en) 2008-10-23
WO2008125366A3 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
AU318442S (en) Footbath
EP2182833A4 (en) Endoscope
GB0716605D0 (en) Skin antiseptics
GB0711342D0 (en) Well treatment
EP2230910A4 (en) Pre-surgical treatment
GB0716532D0 (en) Therapeutic compounds
PL1987765T3 (en) Oximeter
GB0624874D0 (en) Treatment
GB0719518D0 (en) Therapy
GB0724340D0 (en) Novel Therapeutic Agents
GB0707208D0 (en) Novel disease treatments
GB0600692D0 (en) Well treatment
GB0716784D0 (en) Well treatment
GB0822077D0 (en) Novel treatments
GB0607952D0 (en) Novel treatment
GB0717450D0 (en) Medicament
GB0702862D0 (en) Therapeutic compounds
GB0808690D0 (en) Therapeutic use
GB0604460D0 (en) Treatment
GB0708188D0 (en) Therapeutic compounds
GB0716072D0 (en) Therapy
GB0700635D0 (en) Therapy
GB0708186D0 (en) Therapeutic compounds
GB0710732D0 (en) Treatment
GB0724838D0 (en) Effulent treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)